Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 117, Issue 27, Pages 15818-15826Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2006348117
Keywords
atherosclerosis; clonality; smooth muscle cells; efferocytosis; CD47
Categories
Funding
- NIH [R35 HL144475, R01 HL125224, R01 HL123370, R01 HL125863]
- American Heart Association [19EIA34770065, 18POST34030084, A14SFRN20840000]
- Swedish Research Council
- Heart Lung Foundation [2018-02529, 20170265]
- Deutsche Forschungsgemeinschaft [JA 2869/1-1:1]
- Fondation Leducq [18CVD02]
- NIH S10 Shared Instrument Grant [S10RR027431-01]
- Swedish Research Council [2018-02529] Funding Source: Swedish Research Council
- Vinnova [2018-02529] Funding Source: Vinnova
Ask authors/readers for more resources
Atherosclerosis is the process underlying heart attack and stroke. Despite decades of research, its pathogenesis remains unclear. Dogma suggests that atherosclerotic plaques expand primarily via the accumulation of cholesterol and inflammatory cells. However, recent evidence suggests that a substantial portion of the plaque may arise from a subset of dedifferentiated vascular smooth muscle cells (SMCs) which proliferate in a clonal fashion. Herein we use multicolor lineage-tracing models to confirm that the mature SMC can give rise to a hyperproliferative cell which appears to promote inflammation via elaboration of complement-dependent anaphylatoxins. Despite being extensively opsonized with prophagocytic complement fragments, we find that this cell also escapes immune surveillance by neighboring macrophages, thereby exacerbating its relative survival advantage. Mechanistic studies indicate this phenomenon results from a generalized opsoninsensing defect acquired by macrophages during polarization. This defect coincides with the noncanonical up-regulation of so-called don't eat me molecules on inflamed phagocytes, which reduces their capacity for programmed cell removal (PrCR). Knockdown or knockout of the key antiphagocytic molecule CD47 restores the ability of macrophages to sense and clear opsonized targets in vitro, allowing for potent and targeted suppression of clonal SMC expansion in the plaque in vivo. Because integrated clinical and genomic analyses indicate that similar pathways are active in humans with cardiovascular disease, these studies suggest that the clonally expanding SMC may represent a translational target for treating atherosclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available